Skip to content

Pilot Study On Pulsed Electromagnetic Field Therapy For Osteosarcopenia

Pilot Study On Pulsed Electromagnetic Field Therapy For Osteosarcopenia

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05043480
Enrollment
80
Registered
2021-09-14
Start date
2021-10-01
Completion date
2022-12-31
Last updated
2021-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteopenia or Osteoporosis, Sarcopenia

Brief summary

This prospective, single-site, single arm pilot study aims to assess the efficacy of Pulsed Electromagnetic Field (PEMF) exposure in the reduction of the decline in muscle strength, function and bone mineral density (BMD) in osteosarcopenia.

Detailed description

This prospective, single-site, single-arm pilot study aims to assess the efficacy of Pulsed Electromagnetic Field (PEMF) exposure in the reduction of the decline in muscle strength, function and bone mineral density (BMD) in osteo-sarcopenia. For this pilot study, we will recruit 80 participants aged 65 years old and greater with osteo-sarcopenia, to receive PEMF therapy, at 1.5mT, once a week for 10 min to alternate lower limb (10 mins each week) weekly for 16 weeks. Participants will be followed up at baseline, 4, 8 and 12 and 17 weeks. At each follow-up, falls risk will be assessed by Short Physical Performance Battery (SPPB), including 6-minute walk and 5 sit-to-stand tests, Falls Efficacy Scale International (FESI), 3min-NS (3 minute Nutritional Screening) and SARC-F (Strength, Assistance with Walking, Rise from Chair, Climb Stairs and Falls) questionnaires. Muscle strength (hand grip and leg extension) and calf diameter are measured. Blood tests, saliva tests, and DEXA scans will be done at baseline, immediately after first PEMF exposure and week 17 to determine changes in biomarkers for senescence, bone/fat/muscle composition and skeletal muscle mass.

Interventions

DEVICEPEMF

Participants will receive pulsed electromagnetic fields (PEMF) exposure to alternate lower limbs weekly for 16 weeks. Participants will place alternate lower limb into the PEMF machine. Each lower limb will be exposed to 1.5mT magnetic field exposure for 10 mins once a week (total 10 min each week) for 16 weeks.

Sponsors

National University of Singapore
CollaboratorOTHER
Louis Tee
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
65 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

1. Age 65 years old and above, which corresponds to the geriatric patient population seen at the Healthy Ageing clinics and wards 2. Diagnosed with primary osteopenia, including primary osteoporosis, by BMD measurements on DEXA scans 3. Diagnosed with sarcopenia by SARC-F 4. Willing and able to give written informed consent

Exclusion criteria

1. Presence of metallic implants, pacemakers or insulin pumps 2. Presence of rheumatological disease (such as osteoarthritis or rheumatoid arthritis) 3. Presence of secondary osteoporosis (such as hyperparathyroidism, steroid-induced osteoporosis) 4. Presence of end-stage organ failure, including severe dementia or cancer 5. Pregnant women

Design outcomes

Primary

MeasureTime frameDescription
Lower limb strength18 weeksLower limb strength measurement measured by dynamometer
Handgrip strength18 weeksHandgrip strength measurement measured by dynamometer
Short Physical Performance Battery (SPPB)18 weeksValidated assessment tool for balance and lower limb strength (Score from 0 to 12)
6 minute walk test (6MWT)18 weeksDistance walked in a time of 6 minutes (units of meters)

Secondary

MeasureTime frameDescription
Lean muscle and fat mass18 weeksLean muscle and fat mass measured by DEXA scan

Countries

Singapore

Contacts

Primary ContactSanthosh Seetharaman, MBBS
mdcsnks@nus.edu.sg90302683

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026